258 related articles for article (PubMed ID: 33494793)
1. Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial.
Kim ST; Sa JK; Oh SY; Kim K; Hong JY; Kang WK; Kim KM; Lee J
Genome Med; 2021 Jan; 13(1):11. PubMed ID: 33494793
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
3. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.
De Vita F; Borg C; Farina G; Geva R; Carton I; Cuku H; Wei R; Muro K
Future Oncol; 2019 Aug; 15(23):2723-2731. PubMed ID: 31234645
[No Abstract] [Full Text] [Related]
9. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.
Lorenzen S; Thuss-Patience P; Pauligk C; Gökkurt E; Ettrich T; Lordick F; Stahl M; Reichardt P; Sökler M; Pink D; Probst S; Hinke A; Goetze TO; Al-Batran SE
Eur J Cancer; 2022 Apr; 165():48-57. PubMed ID: 35202974
[TBL] [Abstract][Full Text] [Related]
10. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.
Boisteau E; François E; Aparicio T; Le Malicot K; Boulahssass R; Lecomte T; Laurent-Puig P; Guiu B; Paillaud E; Galais MP; Lopez-Trabada Ataz D; Tougeron D; Dourthe LM; Guimbaud R; Samalin E; Moreau M; Louvet C; Lepage C; Lièvre A
Dig Liver Dis; 2022 Jun; 54(6):747-754. PubMed ID: 35351371
[TBL] [Abstract][Full Text] [Related]
11. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
13. Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab.
Masuda Y; Kananazawa Y; Matsuno K; Kakinuma D; Sakurazawa N; Ando F; Hagiwara N; Nomura T; Kato S; Yoshiyuki T; Yoshida H
Anticancer Res; 2022 Mar; 42(3):1599-1605. PubMed ID: 35220257
[TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
Zhang X; Zhou L; Zhou C; Shen L
Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719
[TBL] [Abstract][Full Text] [Related]
15. Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy.
Roviello G; Martina C; Winchler C; De Gennaro Aquino I; Papa F; Buttitta E; Rossi G; Antonuzzo L
J Gastrointest Cancer; 2023 Sep; 54(3):802-808. PubMed ID: 36109437
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Jung M; Ryu MH; Oh DY; Kang M; Zang DY; Hwang IG; Lee KW; Kim KH; Shim BY; Song EK; Sym SJ; Han HS; Park YL; Kim JS; Lee HW; Lee MH; Koo DH; Song HS; Lee N; Yang SH; Choi DR; Hong YS; Lee KE; Maeng CH; Baek JH; Kim S; Kim YH; Rha SY; Cho JY; Kang YK
Gastric Cancer; 2018 Sep; 21(5):819-830. PubMed ID: 29427038
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer.
Nakajima TE; Kadowaki S; Minashi K; Nishina T; Yamanaka T; Hayashi Y; Izawa N; Muro K; Hironaka S; Kajiwara T; Kawakami Y
Clin Cancer Res; 2021 Feb; 27(4):1029-1036. PubMed ID: 33262133
[TBL] [Abstract][Full Text] [Related]
18. A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.
Chen Y; Katayose T; Nagaoka S; Piao Y; Yamaguchi K; Asou H
Gastric Cancer; 2021 Nov; 24(6):1320-1329. PubMed ID: 34050432
[TBL] [Abstract][Full Text] [Related]
19. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M
Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.
Iwai M; Ito D; Asano H; Adachi S; Okada K; Kimura M; Usami E; Matsuo K; Yoshimura T; Teramachi H
Pharmazie; 2018 May; 73(5):309-312. PubMed ID: 29724300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]